M. Aboud, C. Orkin, D. Podzamczer, J. Bogner, D. Baker et al., In: Durable Suppression 2 Years after Switch to DTG+RPV 2-Drug Regimen: SWORD 1&2 Studies, 22nd International AIDS Conference, p.47, 2018.

P. Cahn, J. Fourie, B. Grinsztejn, S. Hodder, J. M. Molina et al., Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients, AIDS, vol.25, pp.929-939, 2011.

P. G. Clay, S. Nag, C. M. Graham, and S. Narayanan, Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens, Medicine (Baltim.), vol.94, p.1677, 2015.

E. Daar, E. Dejesus, P. Ruane, G. Crofoot, G. Oguchi et al., Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, Lancet HIV, vol.3, pp.347-356, 2018.

S. De-meyer, T. Vangeneugden, B. Van-baelen, E. De-paepe, H. Van-marck et al., Resistance profile of darunavir: combined 24-week results from the POWER trials, AIDS Res. Hum. Retrovir, vol.24, pp.379-388, 2008.

E. Dejesus, B. Haas, S. Segal-mauer, S. Segal-maurer, M. N. Ramgopal et al., Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate (TDF)-to a tenofovir alafenamide (TAF)-based regimen through 96 weeks of treatment, AIDS Res. Hum. Retrovir, vol.34, pp.337-342, 2018.

S. Di-giambenedetto, M. Fabbiani, E. Quiros-roldan, A. Latini, G. D'ettorre et al., Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial, J. Antimicrob. Chemother, vol.72, pp.1163-1171, 2017.

. Eacs and . European, AIDS Clinical Society Guidelines, vol.9, 2018.

R. Elion, C. Cohen, J. Gathe, P. Shalit, T. Hawkins et al., Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection, GS-US-216-0105 Study Team, vol.25, pp.1881-1886, 2011.

J. J. Eron, C. Orkin, J. Gallant, J. M. Molina, E. Negredo et al., A week 48 randomized phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients, AIDS, vol.32, pp.1431-1442, 2018.

P. Flynn, S. Komar, S. Blanche, C. Giaquinto, A. Noguera-julian et al., Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE), Pediatr. Infect. Dis. J, vol.33, pp.940-945, 2014.

J. E. Gallant, E. Koenig, J. Andrade-villanueva, P. Chetchotisakd, E. Dejesus et al., Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results, J. Infect. Dis, vol.208, pp.32-39, 2013.

J. M. Gatell, L. Assoumou, G. Moyle, L. Waters, M. Johnson et al., European Network for AIDS Treatment 022 (NEAT022) Study Group, 2019. Immediate vs. deferred switching from a boosted protease inhibitor (PI/r) based regimen to a dolutegravir (DTG) based regimen in virologically suppressed patients with high cardiovascular risk or age ?50 years: final 96 weeks results of NEAT 022 study, Clin. Infect. Dis, vol.68, pp.597-606

P. German, H. C. Liu, J. Szwarcberg, M. Hepner, J. Andrews et al., Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function, J. Acquir. Immune Defic. Syndr, vol.61, pp.32-40, 2012.

V. Joly, C. Burdet, R. Landman, F. Raffi, C. Katlama et al., Promising Results of Dolutegravir + Lamivudine Maintenance in ANRS 167 LAMIDOL Trial, p.458, 2017.

O. F. Laterza, C. P. Price, and M. G. Scott, Cystatin C: an improved estimator of glomerular filtration rate?, Clin. Chem, vol.48, pp.699-707, 2002.

E. Lathouwers, E. Y. Wong, D. Luo, S. Seyedkazemi, S. De-meyer et al., HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies, HIV Clin. Trials, vol.18, pp.196-204, 2017.

A. S. Levey, L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro-3rd et al., CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration, Ann. Intern. Med, vol.150, pp.604-612, 2009.

J. M. Llibre, C. Hung, C. Brinson, F. Castelli, P. M. Girard et al., Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies, Lancet, vol.391, pp.839-849, 2018.

A. Menard, L. Meddeb, H. Tissot-dupont, I. Ravaux, C. Dhiver et al., Dolutegravir and weight gain: an unexpected bothering side effect, AIDS, vol.31, pp.499-1500, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01573735

J. M. Molina, D. Ward, I. Brar, A. Mills, H. J. Stellbrink et al., Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, Lancet HIV, vol.3, pp.357-365, 2018.

J. B. Nachega, V. C. Marconi, G. U. Van-zyl, E. M. Gardner, W. Preiser et al., HIV treatment adherence, drug resistance, virologic failure: evolving concepts, Infect. Disord. -Drug Targets, vol.11, pp.167-174, 2011.

J. Norwood, M. Turner, C. Bofill, P. Rebeiro, B. Shepherd et al., Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens, J. Acquir. Immune Defic. Syndr, vol.76, pp.527-531, 2017.

C. Orkin, E. Dejesus, H. Khanlou, A. Stoehr, K. Supparatpinyo et al., Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial, HIV Med, vol.14, pp.49-59, 2013.

C. Orkin, J. Molina, E. Negredo, J. R. Arribas, J. Gathe et al., Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once-daily complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/ TAF) in virologically suppressed, Lancet HIV, vol.5, issue.1, pp.23-34, 2018.

, Available at, Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services, 2019.

J. A. Perez-molina, R. Rubio, A. Rivero, J. Pasquau, I. Suárez-lozano et al., Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial, Lancet Infect. Dis, vol.15, pp.775-784, 2015.

, Prescribing information for SYMTUZA? (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, Janssen Pharmaceutical Companies, 2018.

F. Raffi, C. Orkin, A. Clarke, L. Slama, J. Gallant et al., Brief Report: long-term (96-Week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults, J. Acquir. Immune Defic. Syndr, vol.75, pp.226-231, 2017.

J. Rockstroh, Y. Yazdanpanah, G. Di-perri, P. E. Sax, J. R. Arribas et al., Switching from TDF to TAF Improves Bone and Renal Safety Independent of Age, Sex, Race, or 3rd Agent: Results from Pooled Analysis (N=3816) of Virologically Suppressed HIV-1 Infected Adults, 2017.

M. S. Saag, C. A. Benson, R. T. Gandhi, J. F. Hoy, R. J. Landovitz et al., Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel, J. Am. Med. Assoc, vol.320, pp.379-396, 2018.

G. Sterrantino, L. Santoro, D. Bartolozzi, M. Trotta, and M. Zaccarelli, Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era, Patient Prefer. Adherence, vol.6, pp.427-433, 2012.

. Symtuza?-(darunavir, tablets Summary of Product Characteristics. Janssen-Cilag International NV, 2017.

B. O. Taiwo, V. Marconi, B. Berzins, C. B. Moser, A. N. Nyaku et al., Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial, Clin. Infect. Dis, vol.66, pp.1794-1797, 2018.

L. Taramasso, E. Ricci, B. Menzaghi, G. Orofino, S. Passerini et al., Weight gain: a possible side effect of all antiretrovirals, Open Forum Infect, 2017.

B. Trottier, J. E. Lake, K. Logue, C. Brinson, L. Santiago et al., Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, phase IIIb study, Antivir. Ther, vol.22, pp.295-305, 2017.

A. M. Wensing, V. Calvez, H. F. Günthard, V. A. Johnson, R. Paredes et al., Update of the drug resistance mutations in HIV-1, Top. Antivir. Med, vol.22, pp.642-650, 2014.

D. Wohl, S. Oka, N. Clumeck, A. Clarke, C. Brinson et al., Brief Report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results, J. Acquir. Immune Defic. Syndr, vol.72, pp.58-64, 2016.